Clinical Trial Detail

NCT ID NCT02498613
Title A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung small cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

pancreatic adenocarcinoma

Therapies

Cediranib + Olaparib

Age Groups: senior adult

No variant requirements are available.